Evidence map›Paper›PMID 40038382›Full record

ArticleScientific reports2025

Current prevalence of hepatitis delta diagnosis in Valencia, Spain.

Enrique Ortega González, María Dolores Ocete Mochón, María Martínez-Roma, Concepción Gimeno Cardona, Neus Gómez Muñoz, Moisés Diago Madrid, Alba Carrodeguas, José Luis González-Sánchez, Marta Plaza de la Torre, Miguel García Deltoro

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Enrique Ortega GonzálezFundació Investigació Hospital General Universitari de Valencia, Valencia, Spain.ORCID http://orcid.org/0000-0002-6105-6740
María Dolores Ocete MochónServicio de Microbiología, Consorcio Hospital General Universitario, Valencia, Spain.ORCID http://orcid.org/0000-0003-2546-105X
María Martínez-RomaFundació Investigació Hospital General Universitari de Valencia, Valencia, Spain.ORCID http://orcid.org/0009-0001-2427-3068
Concepción Gimeno CardonaServicio de Microbiología, Consorcio Hospital General Universitario, Valencia, Spain.ORCID http://orcid.org/0000-0002-3778-5337
Neus Gómez MuñozFundació Investigació Hospital General Universitari de Valencia, Valencia, Spain.ORCID http://orcid.org/0000-0002-4923-0371
Moisés Diago MadridUniversitad de Valencia, Valencia, Spain.ORCID http://orcid.org/0000-0002-8583-2433
Alba CarrodeguasGilead Sciences, Madrid, Spain.ORCID http://orcid.org/0000-0001-8488-0372
José Luis González-SánchezGilead Sciences, Madrid, Spain.ORCID http://orcid.org/0009-0008-8599-7482
Marta Plaza de la TorreFundació Investigació Hospital General Universitari de Valencia, Valencia, Spain.ORCID http://orcid.org/0009-0003-5472-1532
Miguel García DeltoroUniversitad de Valencia, Valencia, Spain. miguel.garcia-deltoro@uv.es.ORCID http://orcid.org/0000-0002-5969-1059

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis delta virus (HDV) is the most aggressive form of chronic viral hepatitis, yet substantial knowledge gaps exist regarding its epidemiology and optimal diagnostic workflows. From February 2019 to March 2022, an HBV screening project was conducted across various healthcare settings in Valencia, Spain. This included twenty-six primary care centers, six sexual and reproductive health centers, three mental health centers, three addiction treatment centers, selected hospital departments, outpatient clinics, and a penitentiary center. A retrospective analysis of HDV diagnostic and prevalence (2007-2020) was followed by prospective HDV screening using reflex testing from April to October 2022. Of 31,995 patients screened, 141 were HBsAg-positive (0.44% seroprevalence). Previously unknown HBV infection prevalence was 0.36%. Among HBsAg-positive patients, 5.15% had HDV IgG/IgM antibodies, and 2% had HDV RNA. Reflex single-step HDV testing increased HDV diagnosis coverage from 24 to 99.4%. This study highlights the effectiveness of reflex HDV testing, which significantly increased diagnostic coverage and simplified the screening process. Reflex testing provides a cost-effective and efficient approach, particularly benefiting high-risk populations such as migrants, who accounted for 77.8% of HBsAg-positive cases. Its implementation is crucial for improving patient outcomes and addressing gaps in HDV diagnosis and management.

Indexed as

Hepatitis DHepatitis Delta VirusAdultAgedFemaleHepatitis B Surface AntigensHumansMaleMass ScreeningMiddle AgedPrevalenceRetrospective StudiesSeroepidemiologic StudiesSpainYoung AdultHepatitis B Surface AntigensCo-infectionHBVHDVPrevalenceScreening

Identifiers

PMID40038382
PMCPMC11880328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.